

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2020

<https://marketpublishers.com/r/C33A165199DEN.html>

Date: April 2020

Pages: 552

Price: US\$ 2,000.00 (Single User License)

ID: C33A165199DEN

Abstracts

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Obstructive Pulmonary Disease - Pipeline Review, H1 2020, provides an overview of the Chronic Obstructive Pulmonary Disease (Respiratory) pipeline landscape.

Chronic obstructive pulmonary disease (COPD) is a group of lung diseases. It is characterized by inability to completely breathe out air from the lungs leading to shortness of breath. The airflow to the lungs is further blocked. Other symptoms include cough, fatigue and chest pain. The disease tends to worsen over the time hence increasing the complications. The risk factors involved in causing COPD include smoking as the primary reason. Exposure to chemicals and air pollution also contribute in the development of COPD.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Obstructive Pulmonary Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 8, 38, 15, 3, 77, 21 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 8 and 2 molecules, respectively.

Chronic Obstructive Pulmonary Disease (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (Respiratory).

The pipeline guide reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Chronic Obstructive Pulmonary Disease (Respiratory) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Chronic Obstructive Pulmonary Disease (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (Respiratory)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Chronic Obstructive Pulmonary Disease (Respiratory).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (Respiratory) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Chronic Obstructive Pulmonary Disease (COPD) - Overview

Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Development

Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Assessment

Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics
Development

Chronic Obstructive Pulmonary Disease (COPD) - Drug Profiles

Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects

Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products

Chronic Obstructive Pulmonary Disease (COPD) - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Companies, H1 2020 (Contd..3), H1 2020

Products under Development by Companies, H1 2020 (Contd..4), H1 2020

Products under Development by Companies, H1 2020 (Contd..5), H1 2020

Products under Development by Companies, H1 2020 (Contd..6), H1 2020

Products under Development by Companies, H1 2020 (Contd..7), H1 2020

Products under Development by Companies, H1 2020 (Contd..8), H1 2020

Products under Development by Companies, H1 2020 (Contd..9), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by 3SBio Inc, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AB Science SA, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AB2 Bio Ltd, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Adamis Pharmaceuticals

Corp, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Afimmune Biopharma Ltd, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aibios Co Ltd, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AlgiPharma AS, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Allinaire Therapeutics LLC, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Amgen Inc, H1 2020

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Angiocrine Bioscience Inc, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

3SBio Inc

AB Science SA

AB2 Bio Ltd

Adamis Pharmaceuticals Corp

Afimmune Biopharma Ltd

Aibios Co Ltd

AlgiPharma AS

Allinaire Therapeutics LLC

Amgen Inc

Angiocrine Bioscience Inc

Apollo Therapeutics LLC

Aquilon Pharmaceuticals SA

Aridis Pharmaceuticals Inc

Ark Biosciences Inc

AstraZeneca Plc

AusBio Ltd

Avidin Ltd

Axolo Pharma Inc

Bai Shuo Beijing Pharmaceutical Technology Co Ltd

Bayer AG

BioMarck Pharmaceuticals Ltd
Boehringer Ingelheim International GmbH
C4X Discovery Holdings Plc
Cambryn Biologics LLC
Celon Pharma SA
Chiesi Farmaceutici SpA
China Resources Pharmaceutical Group Ltd
Cipla Ltd
Circassia Pharmaceuticals Plc
Covenant Therapeutics LLC
CSL Ltd
Cureveda LLC
Cytokinetics Inc
Daewoong Pharmaceutical Co Ltd
Denovo Biopharma LLC
Diffusion Pharmaceuticals Inc
Dimerix Ltd
Domainex Ltd
EmeraMed Ltd
EmphyCorp Inc
Emphymab Biotech LLC
Enzychem Lifesciences Corp
EpiEndo Pharmaceuticals Ehf
EpiTracker Inc
Errant Gene Therapeutics LLC
ethris GmbH
Evaxion Biotech ApS
Exotect LLC
F. Hoffmann-La Roche Ltd
Foresee Pharmaceuticals Co Ltd
Future Medicine Co Ltd
Galapagos NV
GeneFrontier Corp
Gilead Sciences Inc
GlaxoSmithKline Plc
Glenmark Pharmaceuticals Ltd
Grifols SA
iCeutica Inc
Icure Pharmaceutical Inc

InMed Pharmaceuticals Inc
Inmunotek SL
Insmed Inc
Invion Ltd
Ionis Pharmaceuticals Inc
JiangSu Qyuns Therapeutics Co Ltd
Johnson & Johnson
KBP BioSciences Co Ltd
Kither Biotech Srl
Korea United Pharm Inc
Koutif Therapeutics LLC
Kyowa Kirin Co Ltd
LTT Bio-Pharma Co Ltd
Mariposa Health Ltd
MD Healthcare Inc
Mereo Biopharma Group Plc
Meridigen Biotech Co Ltd
Metagone Biotech Inc
MetrioPharm AG
Naegis Pharmaceuticals Inc
NB Health Laboratory Co Ltd
Novabiotics Ltd
Novartis AG
Omnispirant Ltd
OncoArendi Therapeutics SA
Oncostellae SL
Orchid Pharma Ltd
Orphomed Inc
Palo BioFarma SL
PharmaLundensis AB
Pharmaxis Ltd
Prous Institute for Biomedical Research SA
Pulmatrix Inc
Pulmotect Inc
Qu Biologics Inc
Quark Pharmaceuticals Inc
Re-Pharm Ltd
Regeneron Pharmaceuticals Inc
Resolys Bio Inc

Respiratorius AB
Rhizen Pharmaceuticals SA
Santhera Pharmaceuticals Holding AG
Silurian Pharmaceuticals Inc
Silver Valley Pharmaceutical Co Ltd
SolAeroMed Inc
Sparrow Pharmaceuticals Inc
sterna biologicals Gmbh & Co KG
Sulfateq BV
Suzhou Connect Biopharmaceuticals Ltd
Symmune Therapeutics LLC
Synairgen Plc
Synovo GmbH
Syntrix Biosystems Inc
Taiho Pharmaceutical Co Ltd
Teva Pharmaceutical Industries Ltd
TFF Pharmaceuticals Inc
TGV-Inhalonix Inc
Theratrophix LLC
Torrent Pharmaceuticals Ltd
Unity Biotechnology Inc
Verona Pharma Plc
Verra Therapeutics LLC
Vicenna Pharmaceuticals Inc
vTv Therapeutics Inc
Yungjin Pharm Co Ltd
Zai Lab Ltd

I would like to order

Product name: Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/C33A165199DEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C33A165199DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970